(Reuters) - U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for ...

Executives from Impact Analytics and Carters Inc. discuss demographic shifts, changing compositions, weight loss drugs and ...

Pendulum Therapeutics latest innovation comes in the form of a GLP-1 probiotic, acting as an appetite suppressor and healthy ...

If you looked solely at its stock price, you might get the idea that Eli Lilly (NYSE: LLY) is having a bit of an off quarter.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

Novo Nordisk's involve the GLP-1 pathway, while Eli Lilly's treatments activate both GLP-1 and GIP, known as dual GLP-1/GIP ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

People are more likely to develop type 2 diabetes if they are: Experts with UW Health say it is important to remember the ...

We rate McKesson as a 'Strong Buy' with focus on GLP-1 meds, oncology network, and strong Q2 results driving future growth.